Galecto to Participate in Leerink Partners 2026 Global Healthcare Conference
Galecto (NASDAQ: GLTO) will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on March 9, 2026 at 10:40 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Galecto (NASDAQ: GLTO) will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on March 9, 2026 at 10:40 a.m. ET.
According to the company, management will webcast the presentation live and make an archived replay available for 30 days under the Investor Calendar on the company website.
Details
News Market Reaction – GLTO
On Mar 2, the day this news came out, GLTO closed 1.59% above the previous close.
Data tracked by StockTitan Argus for the Mar 2 session.
Key Figures
- Conference date/time
- March 9, 2026 at 10:40 a.m. ET
- Leerink Partners 2026 Global Healthcare Conference fireside chat
- Replay availability
- 30 days
- Archived webcast replay duration after the conference event
Historical Context
-
Closed underwritten offering at $19.00 with full over-allotment exercise.
-
Priced $275M common stock offering at $19.00 per share.
-
Proposed offering of common and Series C preferred stock for R&D funding.
-
Outlined 2026 milestones and pipeline plans, supported by $285M PIPE runway.
-
Announced new COO and CMO and reiterated DMR-001 development timeline.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company working to redefine care for people with hematologic disorders, today announced that company management will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026 at 10:40 a.m. ET.
A live webcast of the Company’s presentation will be available under the “News & Events” tab in the Investor Calendar section of the Company’s website at https://ir.galecto.com/news-and-events/events. An archived replay will be accessible for 30 days following the event.
About Galecto, Inc.
Galecto, Inc. is a clinical-stage biotechnology company advancing a pipeline of antibody therapeutics to transform treatment of a broad spectrum of hematological cancers. Galecto’s pipeline includes a highly differentiated mutant calreticulin (mut-CALR)-driven myeloproliferative neoplasm portfolio targeting essential thrombocythemia and myelofibrosis. Galecto’s pipeline also includes GB3226, a first-in-class preclinical dual inhibitor of ENL-YEATS and FLT3 for the treatment of multiple genetic subsets of acute myeloid leukemia.
Media Contact:
Lia Dangelico
Deerfield Group
lia.dangelico@deerfieldgroup.com
Investor Contact:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.